Potential drug interactions in XXXX therapy: a prevalence study using an advanced screening method.

@entity1 @entity918 @entity5 @entity5176 @entity13091 @entity149 @entity344 @entity6397 @entity1162
BACKGROUND: In @entity5 @entity1 , drug interactions may intensify adverse events or reduce antitumour effects. We assessed the prevalence of potential drug interactions (PDIs) among @entity5 @entity1 on i.v. treatment using an advanced screening method. @entity1 AND METHODS: Data on drugs used for comorbidities, anticancer agents, over-the-counter (OTC) drugs, and comorbidities were collected by means of a structured interview among the @entity1 and review of medical charts. PDIs were identified using electronic (Drug Interaction Facts software, version 4.0) and manual screening methods (peer-reviewed reports). RESULTS: In this study, 278 @entity1 were enrolled. We identified 348 PDIs. Of all @entity1 , 161 (58%) had at least one @entity13091 . Of all PDIs, 34% was classified as major and 60% as moderate. @entity6397 , @entity5176 , antiepileptics, and @entity918 were frequently part of a @entity13091 . Interactions that potentially cause @entity1162 , @entity344 , and @entity149 were also common. In multivariate analysis, an increasing number of drugs [odds ratio (OR) = 1.4, confidence interval (CI) 1.23-1.52; P < 0.001] and the use of an OTC drug (OR = 0.56, CI 0.32-0.97; P = 0.045) were risk factors. CONCLUSIONS: PDIs are common in @entity1 treated for an (haemato-) oncological disease. Screening for potential interactions should take place routinely before administering chemotherapy.
